High call volumes

Our member and provider services may be experiencing higher than normal call volumes from 12/22/25-1/9/26 due to a large number of staff being out of office.  We encourage you to utilize alternative forms of communication including secured messaging through online Member Services and Availity Essentials Provider Portal.

Show More

BCBSND district offices will be closed to the public on Friday, Dec. 26.

This includes Bismarck, Grand Forks, Jamestown and Minot. Need help? We’re here for you! Log in at BCBSND.me or call 844-363-8457.

Show More

We are unable to accept walk-ins on Friday, Dec. 26, and Friday, Jan. 2., due to short staffing.


Show More

May 2025 Pharmacy Policies Updates

Impacting our Commercial line of business only

Blue Cross Blue Shield of North Dakota (BCBSND) continually develops and revises pharmacy policies in response to rapidly changing pharmaceutical requirements. Our commitment is to update the provider community as pharmacy policies are adopted and/or revised.

The following Commercial medical drug policies are new and effective May 1, 2025:

*see www.gatewaypa.com/policydisplay/52 on or after May 1, 2025.

  • Avtozma IV (tocilizumab-anoh)
  • Encelto
  • Omlyclo (omalizumab-igec)
  • Omalizumab-igec
  • Osenvelt (denosumab-bmwo)
  • Stoboclo (denosumab-bmwo)

The following Commercial prior authorization medical drug policies have revisions effective May 30, 2025:

*see www.gatewaypa.com/policydisplay/52

  • Adzynma
  • Akynzeo IV
  • Aldurazyme
  • Bavencio
  • Benlysta
  • Cerezyme
  • Eculizumab
  • Elaprase
  • Elelyso
  • Elfabrio
  • Fabrazyme
  • Imfinzi
  • Imjudo
  • Jemperli
  • Kanuma
  • Keytruda
  • Lamzede
  • Lenmeldy
  • Libtayo
  • Loqtorzi
  • Lumizyme
  • Mepsevii
  • Naglazyme
  • Nexviazyme
  • Niktimvo
  • Opdivo
  • Pombiliti
  • Poteligeo
  • Revcovi
  • Romidepsin
  • Saphnelo
  • Tecentriq IV
  • Tevimbra
  • Tremfya
  • Unloxcyt
  • Ustekinumab
  • Vimizim
  • VPRIV
  • Xenpozyme
  • Yervoy
  • Ziihera
  • Zynyz

The following Commercial post service claim edit medical drug policies have revisions effective May 1, 2025:

*see www.gatewaypa.com/policydisplay/52

  • Alpha-1 Proteinase Inhibitors
  • Beleodaq
  • Brineura
  • Cinvanti
  • Fosaprepitant IV
  • Iluvien
  • Mylotarg